☰ Menu
× Close

Vyripharm is committed to

Helping People Live Better Lives

Quality Assurance and Quality Control is Vyripharm's focus for enhancing public safety, public health and public awareness.

About Us

Standardization for Public Health and Public Safety

Leading Biopharmaceutical/Biotechnology Innovator

Vyripharm® is a leading biopharmaceutical/biotechnology innovator in personalized medicine. Vyripharm’s mission is the integration of traditional and alternative medicine. Vyripharm’s focus is to integrate medical platforms in diagnostic & therapeutic applications in disease areas of infectious diseases, neurological disorders, and cancers.

Vyripharm® is also uniquely positioned to become the standard and exclusive sole source of government-approved licensing for tracking, tracing, certifying, compliance monitoring, and testing for Medical Botantical products slated for human consumption or medical treatments to maintain and improve public health and safety.

Vyripharm® also integrates bio-medical informatics and block-chain technology into a global data collection system for better understanding of diagnosis, therapeutic and treatment outcomes, with the integration of R&D to address different disease states and public safety requirements.

The company has patents in sectors such as Regulatory Testing, Pharmaceutical and Diagnostic Drugs, Bioinformatics, Medical Informatics, Monitoring Technology, and Drug Delivery Systems. The company holds exclusive licenses, issued patents, patents pending and trademarks.

Read More

Integrating traditional medicine with alternative medicine

Novel Drug Development

Pharmaceuticals and Radiopharmaceuticals. Vyripharm develops novel platforms for molecular imaging and therapy.

Contact Us

Latest Updates

Contact Us
Aug. 5 2020

Vyripharm International, Inc. and the National Yang-Ming University Signed a MOU to Develop VYR-206 as a Novel Diagnostic Approach for Neurological Disorders Outcomes Following Treatments

Jun. 15 2020

Vyripharm Biopharmaceuticals and Regis Technologies, Inc. Have Signed Off on a Master Drug Program Agreement for Expediting cGMP Manufacture of Our Antiviral Agents for Diagnostic Evaluation of COVID-19

Mar. 26 2020

Vyripharm Biopharmaceuticals Is in the Development Stage of a Novel Integrated Theranostic Approach for the Treatment of Viral Infections Such as COVID-19

Connect With Us

Contact Us